Fluorouracil

Generic Name: Fluorouracil

Brand Names: Actikerall, Carac, Efudex, Fluoroplex, Tolak

Drug Type: Small Molecule

Chemical Formula: C_₄H_₃FN_₂O_₂

CAS Number: 51-21-8

Unique Ingredient Identifier: U3P01618RT

Background: A pyrimidine analog that is an antineoplastic antimetabolite. It interferes with DNA synthesis by blocking the thymidylate synthetase conversion of deoxyuridylic acid to thymidylic acid.

Indication: For the topical treatment of multiple actinic or solar keratoses. In the 5% strength it is also useful in the treatment of superficial basal cell carcinomas when conventional methods are impractical, such as with multiple lesions or difficult treatment sites. Fluorouracil injection is indicated in the palliative management of some types of cancer, including colon, esophageal, gastric, rectum, breast, biliary tract, stomach, head and neck, cervical, pancreas, renal cell, and carcinoid.

Associated Conditions: Actinic Keratosis (AK), Breast Cancer, Colon Cancer, Gastric Cancer, Pancreatic Cancer, Rectal Cancer, Superficial Basal Cell Carcinoma, Verruca (Warts), Hyperkeratotic actinic keratosis

Associated Therapies: -

Clinical Trials

Pre- and Post-operative FOLFOX Based Therapy for Patients With Colorectal Cancer With Liver Involvement

Phase 2

Terminated

Conditions: Colorectal Cancer
Metastases

Interventions: Drug: Cetuximab
Drug: Bevacizumab
Drug: Leucovorin
Drug: Oxaliplatin
Drug: Fluorouracil

First Posted Date: 2007-10-01

Last Posted Date: 2016-12-20

Lead Sponsor: Washington University School of Medicine

Target Recruit Count: 9

Registration Number: NCT00537823

Locations: 🇺🇸
Washington University School of Medicine, St. Louis, Missouri, United States

Vorinostat, Irinotecan, Fluorouracil, and Leucovorin in Treating Patients With Advanced Upper Gastrointestinal Cancer

Phase 1

Completed

Conditions: Esophageal Cancer
Gastric Cancer
Liver Cancer

First Posted Date: 2007-09-28

Last Posted Date: 2013-06-28

Lead Sponsor: Roswell Park Cancer Institute

Target Recruit Count: 23

Registration Number: NCT00537121

Locations: 🇺🇸
Roswell Park Cancer Institute, Buffalo, New York, United States

Trastuzumab or Observation After Combination Chemotherapy and Trastuzumab in Treating Patients Undergoing Surgery for Stage II or Stage III Breast Cancer

Phase 2

Conditions: Breast Cancer

First Posted Date: 2007-09-24

Last Posted Date: 2013-08-26

Lead Sponsor: Instituto Nacional de Cancerologia, Columbia

Target Recruit Count: 160

Registration Number: NCT00533936

Locations: 🇲🇽
Instituto Nacional de Cancerologia, Mexico City, Distrito Federal, Mexico
🇲🇽
Hospital General de Mexico, Mexico City, Distrito Federal, Mexico

Pre-op Rectal ChemoRad +/- Cetuximab

Phase 2

Completed

Conditions: Rectal Cancer

Interventions: Drug: Cetuximab
Drug: 5-fluorouracil
Radiation: Pelvic irradiation

First Posted Date: 2007-09-10

Last Posted Date: 2016-11-03

Lead Sponsor: US Oncology Research

Target Recruit Count: 139

Registration Number: NCT00527111

Locations: 🇺🇸
Yakima Valley Mem Hosp/North Star Lodge, Yakima, Washington, United States
🇺🇸
Advanced Medical Specialties, Miami, Florida, United States
🇺🇸
Melbourne Internal Medicine Associates, Melbourne, Florida, United States

and more 36 locations

Preoperative Chemo and Chemoradiotherapy for Adenocarcinoma of the Stomach and Gastroesophageal Junction (GEJ)

Phase 2

Completed

Conditions: Stomach Cancer
Gastric Cancer

Interventions: Drug: 5-Fluorouracil
Drug: Folinic Acid
Drug: Oxaliplatin
Radiation: Radiotherapy
Procedure: Surgery

First Posted Date: 2007-09-06

Last Posted Date: 2020-02-10

Lead Sponsor: M.D. Anderson Cancer Center

Target Recruit Count: 58

Registration Number: NCT00525785

Locations: 🇺🇸
University of Texas MD Anderson Cancer Center, Houston, Texas, United States

Docetaxel, 5-Fluorouracil and Oxaliplatin in Adenocarcinoma of the Stomach or Gastroesophageal Junction Patients

Phase 1

Completed

Conditions: Gastrointestinal Diseases

Interventions: Drug: 5-Fluorouracil
Drug: Docetaxel
Drug: Oxaliplatin

First Posted Date: 2007-09-06

Last Posted Date: 2016-10-31

Lead Sponsor: M.D. Anderson Cancer Center

Target Recruit Count: 98

Registration Number: NCT00526110

Locations: 🇺🇸
University of Texas MD Anderson Cancer Center, Houston, Texas, United States

Oxaliplatin-Based Chemotherapy and Chemoradiotherapy or Chemoradiotherapy in Esophageal or Gastroesophageal Carcinoma

Phase 2

Completed

Conditions: Esophageal Cancer
Gastroesophageal Cancer

Interventions: Drug: 5-Fluorouracil
Drug: Oxaliplatin
Radiation: Radiation Therapy
Procedure: Surgery

First Posted Date: 2007-09-06

Last Posted Date: 2015-02-09

Lead Sponsor: M.D. Anderson Cancer Center

Target Recruit Count: 126

Registration Number: NCT00525915

Locations: 🇺🇸
UT MD Anderson Cancer Center, Houston, Texas, United States

Sunitinib, Irinotecan, Fluorouracil, and Leucovorin In Treating Patients With Advanced Stomach Cancer or Gastroesophageal Cancer

Phase 1

Terminated

Conditions: Gastric Cancer
Esophageal Cancer

Interventions: Drug: fluorouracil
Drug: irinotecan hydrochloride
Drug: leucovorin calcium
Drug: sunitinib malate
Other: flow cytometry
Other: pharmacological study

First Posted Date: 2007-09-03

Last Posted Date: 2016-06-21

Lead Sponsor: Roswell Park Cancer Institute

Target Recruit Count: 23

Registration Number: NCT00524186

Locations: 🇺🇸
Roswell Park Cancer Institute, Buffalo, New York, United States

Pharmacogenomically Selected Treatment for Gastric and Gastroesophageal Junction (GEJ) Tumors

Phase 2

Completed

Conditions: Stomach Neoplasms
Esophageal Neoplasms

Interventions: Drug: 5-fluorouracil
Drug: Oxaliplatin
Drug: Leucovorin

First Posted Date: 2007-08-13

Last Posted Date: 2016-01-07

Lead Sponsor: Vanderbilt University

Target Recruit Count: 26

Registration Number: NCT00515216

Locations: 🇺🇸
University of North Carolina, Chapel Hill, North Carolina, United States
🇺🇸
Vanderbilt University Medical Center, Nashville, Tennessee, United States
🇺🇸
Washington University School of Medicine, St. Louis, Missouri, United States

and more 1 locations

Fluorouracil, Oxaliplatin, and Leucovorin in Treating Patients With Metastatic Stomach Cancer or Gastroesophageal Junction Cancer

Phase 2

Completed

Conditions: Gastric Cancer

Interventions: Drug: fluorouracil
Drug: leucovorin calcium
Drug: oxaliplatin
Genetic: gene expression analysis
Genetic: polymorphism analysis
Genetic: protein expression analysis
Other: pharmacological study

First Posted Date: 2007-08-09

Last Posted Date: 2012-11-01

Lead Sponsor: Vanderbilt-Ingram Cancer Center

Target Recruit Count: 33

Registration Number: NCT00514020

Locations: 🇺🇸
Lineberger Comprehensive Cancer Center at University of North Carolina - Chapel Hill, Chapel Hill, North Carolina, United States
🇺🇸
Siteman Cancer Center at Barnes-Jewish Hospital - Saint Louis, St Louis, Missouri, United States
🇺🇸
Vanderbilt-Ingram Cancer Center, Nashville, Tennessee, United States

and more 2 locations

Drug Development Updates

Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.

Home Terms & Conditions Privacy Policy